FIELD: medicine.
SUBSTANCE: series of inventions relates to medicine. Derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity are described. Methods for treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described. Derivatives of decitabine are provided in a non-aqueous formulation, which further stabilizes the derivatives.
EFFECT: derivatives of decitabine are described.
34 cl, 4 dwg, 5 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
DRUG COMBINATIONS | 2014 |
|
RU2708246C2 |
LYOPHILIZED PHARMACEUTICAL COMPOSITIONS | 2016 |
|
RU2723590C2 |
POLYMORPHS OF KINASE INHIBITOR | 2012 |
|
RU2636588C2 |
COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | 2016 |
|
RU2759963C2 |
LIPOSOMAL DRUG FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASM | 2017 |
|
RU2756755C2 |
PHARMACEUTICAL COMPOUND | 2018 |
|
RU2786994C2 |
DRUG DELIVERY SYSTEMS BASED ON MAYTANSINOID | 2018 |
|
RU2783076C2 |
COMBINATION INCLUDING AT LEAST ONE SPLICEOSOME MODULATOR AND AT LEAST ONE INHIBITOR SELECTED FROM BCL2 INHIBITORS, BCL2/BCLXL INHIBITORS, AND BCLXL INHIBITORS, AS WELL AS APPLICATION METHODS | 2018 |
|
RU2783239C2 |
ALBUMIN-BINDING PRODRUGS BASED ON AURISTATIN E DERIVATIVES | 2018 |
|
RU2795101C2 |
BENZIMIDAZOLYLPYRIDYL ESTER COMPOUNDS | 2007 |
|
RU2452469C2 |
Authors
Dates
2016-12-20—Published
2012-08-29—Filed